Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in ovarian cancer
- New trial
Ovarian cancer
Phase 2 pembrolizumab PD-1 antibody plus TLR3 agonist rintatolimod and autologous αDC1 vaccine
This Phase 2, nonrandomized, sequential-design neoadjuvant study at UPMC Hillman Cancer Center tests whether “locoregional chemoimmunotherapy” can improve immune activation and clinical outcomes in chemo-naive stage…
NCT07634094 Exploratory - New trial
Ovarian cancer
Phase 2 mirvetuximab soravtansine FRα-targeted ADC (DM4 tubulin inhibitor) dose-optimizes combos in ovarian cancer.
AbbVie is running this Phase 2, open-label, randomized master protocol (M25-709; sometimes listed as FLORENZA/GOG-3126) to optimize mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)–directed…
NCT07059845 Exploratory - New trial
Ovarian cancer
Phase 1/2 mocertatug rezetecan B7-H4–targeted topoisomerase I ADC combinations in gynecologic tumors.
GlaxoSmithKline’s BEHOLD-2 is a Phase 1/2 randomized, multi-cohort combination study testing mocertatug rezetecan (Mo‑Rez; a B7‑H4–directed antibody-drug conjugate delivering an exatecan-derived topoisomerase I…
NCT06796907 Exploratory - New trial Spotlight
Ovarian cancer
Phase 3 azenosertib WEE1 inhibitor vs chemotherapy in Cyclin E1+ platinum-resistant HGS ovarian cancer.
This global, randomized, open-label Phase 3 study (ASPENOVA; also referenced as GOG-3147/ENGOT-ov109/APGOT-OV27) tests whether azenosertib (ZN-c3)—a first-in-class, oral WEE1 kinase inhibitor from Zentalis…
NCT07546500 Registrational - Trial result
Ovarian cancer
IMNN-001 (intraperitoneal IL-12 plasmid gene therapy) + carbo/taxol nudges PFS/OS upward in newly diagnosed advanced ovarian cancer
IMNN-001 is an intraperitoneal immunotherapy nanoparticle delivering a DNA plasmid encoding IL-12, given weekly alongside neoadjuvant/adjuvant carboplatin/paclitaxel around interval debulking surgery in the…
- New trial Spotlight
Ovarian cancer
Phase 1 XmAb541 CLDN6×CD3 T‑cell–engaging bispecific + XmAb808 B7‑H3×CD28 costimulatory bispecific
Xencor’s open-label Phase 1 study (sequential assignment) dose-escalates then dose-expands XmAb541 with XmAb808 to define safety, dose-limiting toxicities, PK, and early antitumor activity (RECIST 1.1) in CLDN6+…
NCT07593092 Exploratory - Trial result Spotlight
Ovarian cancer
ZW191 (FRα-targeted ADC) posts 52% unconfirmed ORR in platinum-resistant ovarian/endometrial cancers (Phase 1)
ZW191 is a folate receptor α (FRα)-targeting antibody–drug conjugate (ADC) evaluated in the ongoing first-in-human ZWI-ZW191-101 Phase 1/2 study (NCT06555744); this Part 1 dose-escalation readout (data cut: Dec 1,…
NCT06555744 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel cuts death risk 35% in platinum‑resistant ovarian cancer
Relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist intended to reverse GR-driven chemotherapy resistance; in the open-label Phase 3 ROSELLA trial (GOG-3073/ENGOT-ov72; NCT05257408),…
NCT05257408 - Trial result
Ovarian cancer
Pembrolizumab (PD-1) + weekly paclitaxel extends OS in platinum-resistant ovarian cancer (KEYNOTE-B96)
Pembrolizumab is an anti–PD-1 checkpoint inhibitor combined here with weekly paclitaxel (microtubule inhibitor), with optional bevacizumab (anti-VEGF) per investigator, in the randomized double-blind Phase 3…
NCT05116189 - Trial result
Ovarian cancer
SBRT (ablative radiotherapy) yields 95% 1-yr local control in oligorecurrent ovarian cancer
Stereotactic body radiation therapy (SBRT)—a high-dose, image-guided ablative radiotherapy—was tested in a Phase I 3+3 dose-escalation study (NCT03325634) for ovarian/fallopian tube/primary peritoneal cancers with ≤3…
NCT03325634 - New trial Spotlight
Ovarian cancer
Phase 3 trial: IP IMNN-001, a first‐in‐class peritoneal modulator
This randomized, adaptive, open label multicenter study sponsored by Imunon evaluates the safety and efficacy of IP IMNN-001 combined with standard neoadjuvant and adjuvant chemotherapy and maintenance therapy versus…
NCT06915025 Registrational - New trial
Ovarian cancer
Phase 2 Mirvetuximab Soravtansine ADC Targeting FOLR1 with Tubulin Inhibition
This randomized Phase 2 study evaluates the safety and efficacy of mirvetuximab soravtansine, an antibody-drug conjugate delivering DM4 (a tubulin inhibitor) to tumors expressing high folate receptor alpha in…
NCT06682988 Exploratory - Trial result
Ovarian cancer
Avutometinib + defactinib delivers 31% ORR (44% in KRAS‑mut) in recurrent low‑grade serous ovarian cancer (LGSOC)
Avutometinib is an oral “RAF/MEK clamp” that locks MEK in an inactive state while preventing RAF feedback, and defactinib blocks focal‑adhesion kinase; together they target MAPK signaling and stromal crosstalk. In…
- Trial result
Ovarian cancer
PARP-VEGF Duo Niraparib + Bevacizumab Posts 61-Month OS in Advanced Ovarian Cancer Maintenance
Niraparib, an oral PARP inhibitor, paired with the anti-VEGF antibody bevacizumab was evaluated in the single-arm phase 2 OVARIO trial (NCT03326193). Among 105 stage IIIB-IV patients who achieved at least a partial…
NCT03326193 - New trial
Ovarian cancer
Phase I/II saruparib PARP1 inhibitor trial
This master protocol study, sponsored by AstraZeneca, evaluates novel biomarker-guided anticancer treatments in participants with advanced/recurrent ovarian, fallopian tube, or primary peritoneal cancer. In Substudy…
NCT07060365 First-in-human - Trial result Spotlight
Ovarian cancer
Avutometinib + Defactinib (RAF-MEK clamp / FAK blocker) Posts 42% ORR and 20 mo PFS in Refractory Low-Grade Serous OC (LGSOC)
In the first-in-human phase 1 FRAME trial (NCT03875820), 26 heavily pre-treated low-grade serous ovarian cancer patients received intermittent avutometinib 3.2 mg once daily (BIW, 3-weeks-on/1-off) plus continuous…
NCT03875820 - New trial
Ovarian cancer
Phase III Olaparib PARP Inhibitor Maintenance in Ovarian Cancer
This phase III trial compares one versus two years of maintenance olaparib—with or without bevacizumab—in patients with BRCA1/2-mutated or HRD+ stage III-IV ovarian cancer following first-line platinum-based…
NCT06580314 Registrational - New trial
Ovarian cancer
Phase 3 trial: Trastuzumab Deruxtecan, HER2-directed ADC with topoisomerase I inhibition.
This Phase 3 randomized, open-label trial by Daiichi Sankyo compares T‑DXd with bevacizumab combination therapy versus bevacizumab monotherapy as first-line maintenance for patients with stage 3/4 high-grade…
NCT06819007 Registrational - Trial result
Ovarian cancer
LY4170156 Exatecan-Linker FRα ADC Delivers 55% ORR in Late-Line Platinum-Resistant Ovarian Cancer
LY4170156 is an Fc-silent antibody–drug conjugate targeting folate-receptor-α, armed with an exatecan payload via a polysarcosine linker. In platinum resistant ovarian cancer, 35-40% of tumors have high FRα…
NCT06400472 - Trial result
Ovarian cancer
CUSP06 CDH6-Targeted Exatecan ADC Shows 36% ORR (50% at ≥4 mg/kg) in Biomarker-Unselected Platinum Refractory/-Resistant Ovarian Cancer
CUSP06 is a cadherin-6 (CDH6)–directed antibody-drug conjugate bearing an exatecan payload (DAR 8) given Q3W in the first-in-human Phase 1a study CUSP06-1001 (NCT06234423). An estimated 65-85% of patients with…
NCT06234423 - Trial result
Ovarian cancer
Pembrolizumab + Lenvatinib (PD-1 + VEGFR/MET/FGFR TKI) Hits 30% ORR and 76% 6-mo PFS in Chemoresistant Clear-Cell Ovarian Cancer
Pembrolizumab, an anti-PD-1 antibody, was paired with the multi-kinase anti-angiogenic agent lenvatinib in a two-stage, single-arm phase 2 trial (NCT05296512). Thirty women with recurrent or persistent clear-cell…
NCT05296512 - New trial
Ovarian cancer
Phase II Mirvetuximab Soravtansine ADC, FOLR1-directed tubulin inhibitor
This single-arm Phase II trial at University of Alabama at Birmingham evaluates neoadjuvant carboplatin plus mirvetuximab in advanced-stage serous ovarian cancer with high FRα expression. The study documents…
NCT04606914 - Trial result
Ovarian cancer
CA125-Targeted Oregovomab Added to Carboplatin/Paclitaxel Hits 10-Year OS 121 mo vs 65 mo in Optimally Debulked Stage III/IV Ovarian Cancer
Oregovomab is a monoclonal antibody that engages host immunity against the protein CA125, which is expressed in ovarian cancer cells. In the randomized QPT-ORE-002 Phase II trial (NCT01616303), 97 women with…
NCT01616303 - Trial result
Ovarian cancer
IL-12 Gene Therapy IMNN-001 Adds 13-Month OS to Front-Line Chemo in Advanced Ovarian Cancer
IMNN-001 works by stimulating local production of IL-12, which activates immune cells to attack the cancer. In the randomized phase I/II OVATION-2 trial (NCT03393884), 112 women with stage III/IV epithelial ovarian…
NCT03393884 - New trial
Ovarian cancer
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Dana Farber is investigating the maximum tolerable dose of DT2216—a selective BCL-xL degrader—administered with weekly paclitaxel in patients with recurrent platinum-resistant ovarian cancer, using a Bayesian Optimal…
NCT06964009 - New trial
Ovarian cancer
Phase II Trial: Mirvetuximab Soravtansine & Olaparib Maintenance in Recurrent Ovarian Cancer
University of Colorado, Denver is evaluating a maintenance therapy combining mirvetuximab soravtansine—a FOLR1-directed ADC—with olaparib in patients with platinum-sensitive, recurrent high-grade ovarian, peritoneal,…
NCT05887609 - New trial
Ovarian cancer
Phase 2 Study of Relacorilant Combo in Advanced Ovarian Cancer (BELLA)
This Phase 2 trial evaluates the safety and efficacy of intermittent relacorilant combined with nab-paclitaxel and bevacizumab in patients with advanced, platinum-resistant ovarian cancer, focusing on high-grade…
NCT06906341 - New trial
Ovarian cancer
Adaptive Trial Evaluates COM701 Maintenance in Relapsed Platinum-Sensitive Ovarian Cancer
Compugen Ltd is investigating COM701—a poliovirus receptor-related immunoglobulin-directed antibody—as a maintenance treatment to delay progression in patients with relapsed platinum sensitive ovarian cancer in a…
NCT06888921
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.